Building B580, Room 2011
Babraham Research Campus
19 articles with PhoreMost Ltd
9/10/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
2/7/2020Pharma and biotech companies strengthen their leadership teams and boards with this weeks appointments.
PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has made two appointments to strengthen its leadership team, as the Company positions itself for growth.
PhoreMost’s next-generation phenotypic screening platform, SITESEEKER, to identify novel targets for Otsuka's therapeutics discovery programmes
PhoreMost and Otsuka Pharmaceutical Co. entered into a multi-project collaboration to seek out disease-relevant pathways that can be exploited for the development of gene therapies to treat different illnesses.
1/9/2020Pharma and biotech companies from across the globe provide business and pipeline updates.
PhoreMost to deploy its SITESEEKER platform to identify novel targets for Boehringer Ingelheim's discovery programmes
11/7/2019Biotech and pharmaceutical companies from across the globe provide updates on their business and pipelines.
PhoreMost and Sentinel Oncology Expand Collaboration to Jointly Accelerate Novel Glioma Therapeutic Through Preclinical Development
Lead allosteric PLK1 inhibitor to progress through preclinical and IND enabling studies
7/19/2019Pharma and biotech companies from across the globe expand their leadership teams and boards.
Board appointment will help guide target identification and drug discovery
7/11/2019Companies from across Europe, Asia and around the globe share pipeline and business updates.
inStem’s Centre for Chemical Biology and Therapeutics to work with PhoreMost to progress selected targets
6/27/2019Biotech and pharma companies from across the globe share pipeline and business updates.
Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target
Ligand will now apply its Vernalis Design Platform (VDP) to design small molecule inhibitors against the target, to help rapidly progress compounds through hit-to-lead and lead optimization stages.
The collaboration will see o2h deploy its expertise in medicinal chemistry to help progress PhoreMost’s portfolio rapidly through the hit-to-lead and lead-optimisation stages of drug discovery.
PhoreMost and Sixth Element Capital Announce Creation and Investment in NeoPhore, an Immuno-Oncology Company
Sixth Element Capital LLP announces a £3 million investment in NeoPhore, a spin out from Cambridge, UK based PhoreMost Ltd
PhoreMost Ltd And University of Cambridge Collaborate To Identify Innovative Drug Targets For Neurodegenerative Disease
PhoreMost Ltd And The Wistar Institute Collaborate To Identify New Druggable Targets In Cancer, Immunotherapy And Aging